Knowledge, attitudes, and practices regarding hantavirus disease and acceptance of a vaccine trial in rural communities of southern Chile
Gestores bibliográficos
item.contributor.advisor
ORCID:
Journal Title
Journal ISSN
Volume Title
Publisher
Taylor & Francis Online
item.page.isbn
item.page.issn
item.page.issne
item.page.doiurl
item.page.extent
8
item.page.accessRights
item.page.other
item.page.references
Abstract
Andes hantavirus cardiopulmonary syndrome, transmitted by Oligoryzomys longicaudatus, has no approved treatment, a case fatality rate of 35%, and documented person-to-person transmission. An Andes vac...
Description
item.page.coverage.spatial
item.page.sponsorship
Citation
Human Vaccines & Immunotherapeutics Volume 13, 2017, Issue 4, pages 808-815
item.page.dc.rights
item.page.dc.rights.url
Estadísticas de uso
1 0,8 0,5 0,3 0
Septiembre 2025Octubre 2025Noviembre 2025Diciembre 2025Enero 2026Febrero 2026Marzo 2026